Pharmacogenetics and Genomics

Papers
(The TQCC of Pharmacogenetics and Genomics is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
MEG3 in hematologic malignancies: from the role of disease biomarker to therapeutic target15
Establishing national reference materials for genetic testing of cytochrome P45014
Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients11
Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation11
Luteal phase stimulation in double ovarian stimulation cycles is not affected by the follicle-stimulating hormone (FSH) receptor genotype: double ovarian stimulation is beneficial independently of the10
Common dihydropyrimidinase (DPYS) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort9
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation9
Unraveling the genetic link: an umbrella review on HLA-B*15:02 and antiepileptic drug-induced Stevens–Johnson syndrome/toxic epidermal necrolysis9
The functional role of inherited CDKN2A variants in childhood acute lymphoblastic leukemia9
The impact of genetic variations in FPGS, MTHFR, and ATIC on methotrexate response among pediatric patients with acute lymphoblastic leukemia8
Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort7
Effect of CYP2D6 genetic variation on patient-reported symptom improvement and side effects among children and adolescents treated with amphetamines7
Annual Scientific Meeting of the Pharmacogenomics Global Research Network (PGRN) June 12-13, 2023 Memphis, TN, USA7
PharmGKB summary: disulfiram pathway6
Effects of CYP3A5*3 genetic polymorphisms on the pharmacokinetics of perampanel in Chinese pediatric patients with epilepsy6
Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy6
Updating probability of pathogenicity for RYR1 and CACNA1S exon variants in individuals without malignant hyperthermia after exposure to triggering anesthetics6
Genome-wide DNA methylation profile of peripheral blood lymphocytes from subjects with nonsteroidal anti-inflammatory drug-induced respiratory diseases5
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis5
N-acetyltransferase 2 haplotype modifies risks for both dyslipidemia and urinary bladder cancer5
HDL-C and creatinine levels at 1 month are associated with patient 12-month survival rate after kidney transplantation4
Pharmacogenomic allele coverage of genome-wide genotyping arrays: a comparative analysis4
Mouse nerve growth factor suppresses neuronal apoptosis in valproic acid-induced autism spectrum disorder rats by regulating the phosphoinositide-3-kinase/serine/threonine kinase signaling pathway4
Integrating pharmacogenetics in sport medicine: enhancing treatment precision and preventing unintentional doping violation4
Pharmacogenetic study of methadone treatment for heroin addiction: associations between drug-metabolizing gene polymorphisms and treatment efficacy4
The c.415C>T polymorphism in NUDT15 is more frequent than the polymorphisms in TPMT in Chilean patients who use thiopurine drugs4
Genetic polymorphisms effect on cyclophosphamide’s tolerability and clinical efficacy in Egyptian patients with lupus nephritis4
Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease3
Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia3
Identification of potential druggable targets of cell cycle with small-molecule inhibitors in oral squamous cell carcinoma3
Updated analysis of the pharmacogenomics of pediatric bronchodilator response3
Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension3
Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care3
Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens3
Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects3
0.061904907226562